Phyo T. Htoo

Brigham and Women's Hospital/Harvard Medical School
Boston, Massachusetts, United States

Johnson & Johnson (Employment)

Presentation(s):

• Effectiveness and Safety of Empagliflozin in Routine Care: Results from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study

  Friday, August 26, 2022
  6:15 PM - 6:20 PM CEST

• Emulating Stratified Randomized Trials by Propensity Score Methods

  Saturday, August 27, 2022
  9:15 AM - 9:30 AM CEST

• Cardiovascular Effectiveness of Empagliflozin vs. Glucagon-like peptide-1 Receptor Agonists or Liraglutide in the EMPRISE Study

  Sunday, August 28, 2022
  9:30 AM - 9:45 AM CEST

• Using Iterative Causal Forest to Identify Heterogeneous Treatment Effects: Sodium-glucose Cotransporter-2 inhibitors versus Glucagon-like Peptide-1 Receptor Agonists on Hospitalization for Heart Failure

  Sunday, August 28, 2022
  9:45 AM - 10:00 AM CEST

• Risk of Hypoglycemia with Sodium Glucose cotransporter-2 Inhibitors vs. Alternative Glucose Lowering Medications in Patients with and Without Baseline Use of Insulin or Sulfonylurea

  Sunday, August 28, 2022
  2:30 PM - 2:45 PM CEST